Estrella Immunopharma Inc (ESLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.65+0.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ESLA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||
| R&D Expenses | 7.0 | 10.2 | 4.1 | 10.5 | — | — |
| Operating Income | (9.8) | (13.1) | (7.3) | (11.1) | (1.6) | (0.2) |
| Earnings from Continuing Operations | ||||||
| Interest & Investment Income | — | — | — | — | 0.7 | 0.0 |
| EBT, Incl. Unusual Items | (10.0) | (13.1) | (7.3) | (11.1) | (0.9) | (0.2) |
| Income Tax Expense | — | 0.0 | 0.0 | — | 0.1 | 0.0 |
| Net Income | ||||||
| Net Income | (10.0) | (13.1) | (7.3) | (11.1) | (1.0) | (0.2) |
| Per Share | ||||||
| Basic EPS | (0.23) | (0.35) | (0.27) | (36.35) | — | — |
| Diluted EPS | (0.23) | (0.35) | (0.27) | (36.35) | — | — |
| Basic Weighted Avg Shares | 43.0 | 36.8 | 27.1 | 0.3 | — | 1.2 |
| Diluted Weighted Avg Shares | 43.0 | 36.8 | 27.1 | 0.3 | — | 1.2 |
| Supplemental | ||||||
| EBIT | (9.8) | (13.1) | (7.3) | (11.1) | (1.6) | (0.2) |
| Effective Tax Rate | — | — | — | — | -8.8% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.